Sclerotherapy with XXXX for recurrent cystic thyroid nodule.

@entity1 @entity1012 @entity5409 @entity5
We have adopted @entity1012 as a sclerosing agent in the treatment of cystic predominant thyroid nodules and have analyzed our findings to assess the efficacy of intralesional instillation of @entity1012 . From 1992 through 1993, 48 @entity1 with recurrent or progressive cystic thyroid nodules after 2 or 3 aspirations alone, and whom were cytologically negative for @entity5 , were used for this study. The @entity1012 solution was prepared by dissolving 0.1 mg of @entity1012 in 2 ml of physiologic saline and it was instilled in the amount of 1/10-to-1/5 of the aspirated cystic fluid. A repeated course of therapy was given up to 3 times when sufficient resolution was not obtained 4-to-6 weeks after treatment. The mean number of treatment sessions per @entity1 was 1.5. Throughout the follow-up period from 30-to-45 months (mean, 38 months), 32 (66.7%) @entity1 experienced an almost complete disappearance (< 0.05 cm in diameter) of the @entity5409 , and 12 (25%) @entity1 responded partially by having it decrease by more than half (> 0.5 cm in diameter) of the initial cyst size, and none of these @entity1 required further treatment. The remaining 4 (8.3%) @entity1 showed insufficient resolution despite 3 courses of therapy and 2 of these @entity1 underwent thyroidectomy, in which the lesion proved benign in both cases. All of the @entity1 tolerated the sclerotherapy well. No significant local complications attributed to this treatment were observed. However, a low-grade fever was observed in 26 (54.2%) @entity1 for 2 to 5 days after instillation, which subsided with symptomatic treatment. On the basis of our experience, @entity1012 sclerotherapy appears to be safe, simple and effective, and can be a useful alternative treatment for cystic thyroid nodules.
